Aciraft-RD Capsules

Product Description

Aciraft-RD combines rabeprazole for gastric acid suppression with sustained-release domperidone, a prokinetic agent used in selected patients to improve upper gastrointestinal motility and control associated nausea or fullness.

The formulation is intended for physician-directed management of acid-related gastrointestinal disorders where both acid control and motility support are considered appropriate.

Composition / Nutritional Information

• Rabeprazole Sodium IP — 20 mg (enteric-coated pellets)
• Domperidone IP — 30 mg (sustained-release pellets)
• Excipients — q.s.

Indications / Intended Support

• GERD
• Acid-peptic disorders
• Functional dyspepsia
• Acidity associated with nausea, bloating or delayed gastric emptying

Key Product Features

• Dual acid-control and motility-support approach
• Targeted enteric-coated and sustained-release delivery
• May reduce reflux-associated upper GI discomfort
• Physician-supervised combination therapy